Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).
Nathan Fowler(Repligen (United States)), Beth Christian(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Raquel Izumi, Don A. Stevens(Norton Healthcare), Deborah M. Stephens(University of North Carolina at Chapel Hill), Peter Martin(Northwestern University), Ming Yin(Brigham and Women's Hospital), Sonali M. Smith(University of Chicago), Minoti Hiremath(Yale University), Tycel Phillips(Michigan Medicine), Naomi Hunder(Fred Hutch Cancer Center), Richy Agajanian(Oncology Institute of Hope and Innovation), Jean Cheung(AstraZeneca (United States)), Morton Coleman(Cornell University), J. Greg Slatter(Amgen (United States)), Parameswaran Venugopal(Rush University Medical Center)
Cited by 19
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k